Venturi Wealth Management LLC Has $446,000 Stock Holdings in STERIS plc (NYSE:STE)

Venturi Wealth Management LLC boosted its holdings in STERIS plc (NYSE:STE) by 45.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,837 shares of the medical equipment provider’s stock after acquiring an additional 574 shares during the quarter. Venturi Wealth Management LLC’s holdings in STERIS were worth $446,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Massachusetts Financial Services Co. MA raised its stake in shares of STERIS by 13.7% in the second quarter. Massachusetts Financial Services Co. MA now owns 6,442,805 shares of the medical equipment provider’s stock valued at $1,414,453,000 after acquiring an additional 778,613 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in STERIS by 7,418.7% in the third quarter. Assenagon Asset Management S.A. now owns 309,771 shares of the medical equipment provider’s stock worth $75,132,000 after purchasing an additional 305,651 shares in the last quarter. Impax Asset Management Group plc grew its holdings in shares of STERIS by 29.7% during the second quarter. Impax Asset Management Group plc now owns 1,150,517 shares of the medical equipment provider’s stock worth $251,663,000 after purchasing an additional 263,383 shares during the last quarter. American Century Companies Inc. increased its stake in shares of STERIS by 1,946.3% in the second quarter. American Century Companies Inc. now owns 270,311 shares of the medical equipment provider’s stock valued at $59,344,000 after buying an additional 257,101 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of STERIS by 7.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,738,630 shares of the medical equipment provider’s stock valued at $390,880,000 after buying an additional 120,616 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on STE. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research note on Friday, November 8th. StockNews.com cut STERIS from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 29th. KeyCorp upped their price target on STERIS from $255.00 to $265.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. JMP Securities reiterated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research report on Wednesday, August 7th. Finally, Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $253.00.

STERIS Stock Up 0.4 %

Shares of STE opened at $222.73 on Wednesday. The company has a current ratio of 2.41, a quick ratio of 1.49 and a debt-to-equity ratio of 0.33. STERIS plc has a 12 month low of $195.47 and a 12 month high of $248.24. The firm’s 50 day moving average is $231.90 and its 200-day moving average is $228.11. The stock has a market capitalization of $21.96 billion, a PE ratio of 50.85 and a beta of 0.85.

STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, topping the consensus estimate of $2.12 by $0.02. STERIS had a net margin of 8.02% and a return on equity of 13.78%. The business had revenue of $1.33 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same quarter in the prior year, the business posted $2.03 earnings per share. STERIS’s revenue was up 7.3% compared to the same quarter last year. Equities research analysts forecast that STERIS plc will post 9.15 EPS for the current year.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be issued a dividend of $0.57 per share. The ex-dividend date is Tuesday, November 19th. This represents a $2.28 annualized dividend and a dividend yield of 1.02%. STERIS’s dividend payout ratio (DPR) is presently 52.05%.

Insiders Place Their Bets

In other news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the transaction, the chief financial officer now owns 42,930 shares in the company, valued at approximately $10,603,710. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.14% of the company’s stock.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.